Related Experiment Video
Updated: Aug 10, 2025
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
[Severity of COVID-19 in patients with multiple sclerosis in Argentina]
Adriana Carrá1, Carlos Vrech2, Gustavo Valitutti3
1Hospital Británico de Buenos Aires, Argentina.
Introduction:
There is limited local information on the risk of severe COVID-19 infection in patients with multiple sclerosis (MS) who are receiving disease-modifying treatments (DMT). The aim of the study was to assess the impact of COVID-19 disease (severity and lethality) in MS patients receiving DMT.
Methods:
The study was performed on a prospective cohort with EM. We included 111 patients with MS and a confirmed diagnosis of COVID-19 treated with DMT and followed up until the resolution of COVID-19.
Results:
A total of six patients (5.4%; 95% CI: 2-11.4%) developed severe COVID-19 defined as requiring hospitalization in intensive care unit or death and three died (crude case fatality rate of 2.7%; 95% CI: 1.1-4.3%). The age-adjusted case fatality rate was 1.5% (95% CI: 0.6-2.4%). The factor that was independently associated with severe COVID-19 was age (OR 1.1; CI 1.0-1.3; p < 0.05) with a trend in the Expanded Disability Status Scale (EDSS) = 6 (OR 6.2; CI 0.6-56.4; p = 0.10).
Conclusion:
The lethality due to COVID-19 in MS patients is low, and severity was significantly associated with age and showed a trend with EDSS = 6.
Insights
COVID-19 severity and fatality in multiple sclerosis (MS) patients on disease-modifying treatments (DMT) were assessed. Lethality was low, with age being a significant factor for severe COVID-19 outcomes.
Area of Science:
- Neurology
- Infectious Diseases
- Epidemiology
Context:
- Limited data exists on severe COVID-19 outcomes for multiple sclerosis (MS) patients undergoing disease-modifying treatments (DMT).
- Assessing COVID-19 impact in this vulnerable population is crucial for clinical management.
Purpose:
- To evaluate the severity and lethality of COVID-19 in patients with MS receiving DMT.
- To identify factors associated with severe COVID-19 outcomes in this cohort.
Summary:
- A prospective cohort study included 111 MS patients with confirmed COVID-19 on DMT.
- Severe COVID-19 (ICU admission or death) occurred in 5.4% of patients; 2.7% died.
- Age was independently associated with severe COVID-19; a trend was observed with an Expanded Disability Status Scale (EDSS) of 6.
Impact:
- The study indicates a low lethality rate of COVID-19 among MS patients on DMT.
- Age is a key predictor of severe COVID-19 in MS patients, highlighting the need for targeted preventive strategies.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...